CLAIM #23077 · EXC (EXC) · 2021Q3 earnings call · Nov 3, 2021 · due Dec 31, 2021
“The remainder of the first quarter drag is expected to reverse in the fourth quarter, and is not expected to impact our full year results.”
Joe Nigro · CFO
In context
“cases. ExGen earned $0.44 per share in the third quarter. Generation and Constellation both performed well during the quarter. We continue to make progress on levers we identified to mitigate the Texas loss, and we expect it will take the full year to realize all of the savings. Realized gains in our decommissioning trust funds partially offset the unrealized losses from our Constellation technology venture investments, which are mark-to-market in every quarter until realized. At our holding Company, we benefited from expected income tax favorability in the third quarter. And as a reminder, our holding Company incurred $0.12 per share drag in the first quarter, associated with how consolidated full-year tax expenses are booked due to the impact of the losses incurred at ExGen and Texas. The remainder of the first quarter drag is expected to reverse in the fourth quarter, and is not expected to impact our full year results. Turning to guidance, we are narrowing our 2021 EPS guidance range to $2.70 to $2.90 per share, from $2.60 to $3 per share previously. Our updated guidance considers reversal of the retirements of the Byron and Dresden nuclear stations, as well as execution of the EDF put, and our continued additional disciplined approach to cost management. We are delivering on our financial commitments and are confident, we will be within our revised range at year-end. On Slide 9, we show our quarter-over-quarter earnings walk. The dollar per 9 -- $9 per share in the third quarter of this year was $0.05 per share higher than the third quarter of 2020. Exelon Utilities inclusive of holding Company earnings, we're $0.08 per share higher compared to last year. The earnings growth was driven primarily by hi”
Verify independently
SEC filings for EXC ↗ · Claim quote is verbatim from the 2021Q3 earnings call.